期刊
MOLECULAR MEDICINE REPORTS
卷 3, 期 4, 页码 613-619出版社
SPANDIDOS PUBL LTD
DOI: 10.3892/mmr_00000305
关键词
proteasome inhibitor; histone deacetylase inhibitor; HeLa cells; apoptosis
Proteasome inhibitors and histone deacetylase (HDAC) inhibitors are two promising groups of anti-cancer agents. In this study, we examined the apoptotic effects of the proteasome inhibitor bortezomib and HDAC inhibitor suberoylanilide hydroxamic acid (SAHA) in human cervical carcinoma He La cells. Compared to treatment with bortezomib or SAHA alone, co-exposure with these two agents synergistically resulted in the massive apoptosis of He La cells, consistent with a significant increase in caspase-3 activation. We then investigated the mechanisms underlying this effect. The combination of bortezomib and SAHA caused an increase in the ratio of bax/bcl-2 expression, inhibited the nuclear transportation of NF-kappa B, and down-regulated Akt expression and phosphorylation in He La cells. In conclusion, bortezomib and SAHA cooperatively stimulate apoptosis in He La cells through the inhibition of several cyto-protective signalling pathways. This is the first report of synergistic apoptotic effect achieved with a proteasome inhibitor and HDAC inhibitor in He La cells. Thus, the results build the framework for clinical trials using combined proteasome and HDAC inhibition in the treatment of human cervical carcinoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据